Augmenting the Immunogenicity of Synthetic MUC1 Peptide Vaccines in Mice

摘要: Abstract Human mucin MUC1 is abundantly expressed in some cancers of epithelial origin and largely restricted to the apical surface secretory cells normal tissues. It is, therefore, a potential target for cancer immunotherapy. In preparation clinical trials, vaccines containing synthetic peptides different lengths sequences mixed with various adjuvants or covalently attached, using linker methods, protein carrier keyhole limpet hemocyanin (KLH) were studied mice. (containing 30 amino acids), plus QS-21 Bacillus Calmette-Guerin , incapable inducing antibody. However, conjugated KLH (MUC1-KLH), QS-21, induced high titer antibody against immunizing MUC1-expressing tumor cells. Although T-cell responses, including delayed-type hypersensitivity, lymphocyte proliferation, CTL, not observed mice immunized these vaccines, significant protection from cell challenge MUC1-KLH was observed. Based on studies, vaccine conjugate prepared m -maleimidobenzoyl- N -hydroxysuccinimide ester linker, has been constructed testing trials.